Phase 3 drug trial for rare chronic kidney disease achieves key ...
Dimerix Limited announced successful interim Phase 3 trial results for DMX-200, a treatment for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The trial involved 72 patients, with plans to expand to more countries and include children over 12. DMX-200 was co-invented by Professor Kevin Pfleger, Dr James Williams, and Liddy McCall, aiming to address the high unmet need in FSGS treatment.
Reference News
Dimerix Limited announced successful interim Phase 3 trial results for DMX-200, a treatment for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. The trial involved 72 patients, with plans to expand to more countries and include children over 12. DMX-200 was co-invented by Professor Kevin Pfleger, Dr James Williams, and Liddy McCall, aiming to address the high unmet need in FSGS treatment.